{"id":740049,"date":"2023-03-14T16:34:00","date_gmt":"2023-03-14T20:34:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/"},"modified":"2023-03-14T16:34:00","modified_gmt":"2023-03-14T20:34:00","slug":"zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/","title":{"rendered":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Eleven abstracts accepted for poster presentation highlight company\u2019s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates<\/i><\/li>\n<li><i>Management will host a conference call on April 18<sup>th<\/sup> at 6:30 pm Eastern Standard Time (EST)<\/i><\/li>\n<\/ul>\n<p>VANCOUVER, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nZymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 \u2013 19, 2023.\n<\/p>\n<p>\n\u201cAACR represents an important opportunity for us to share recent progress in developing the next generation of novel therapeutics and highlights the unique capabilities of our proprietary engineering platforms and integrated technologies,\u201d stated Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. \u201cThe acceptance of eleven abstracts reflects the rapid progress we have made in developing our robust and differentiated pipeline. During the meeting we look forward to sharing new preclinical data on our anticipated 2024 IND candidates, ZW171 and ZW191, as well as other programs that represent potential future therapeutic opportunities and areas of interest.\u201d\n<\/p>\n<p><b>Presentation Details<\/b><\/p>\n<p><b>Antibody Drug Conjugates<\/b><\/p>\n<p>\nTitle: <i>Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery<br \/>\n<br \/><\/i>Abstract: 1538<br \/>\n<br \/>Session Category: Experimental and Molecular Therapeutics<br \/>\n<br \/>Session Title: Antibody Drug Conjugates\n<\/p>\n<p>\nTitle: <i>ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload<br \/>\n<br \/><\/i>Abstract: 2641<br \/>\n<br \/>Session Category: Experimental and Molecular Therapeutics<br \/>\n<br \/>Session Title: Antibody Technologies\n<\/p>\n<p>\nTitle: <i>ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload<br \/>\n<br \/><\/i>Abstract: 1533<br \/>\n<br \/>Session Category: Experimental and Molecular Therapeutics<br \/>\n<br \/>Session Title: Antibody Drug Conjugates\n<\/p>\n<p>\nTitle: <i>ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload<br \/>\n<br \/><\/i>Abstract: 2658<br \/>\n<br \/>Session Category: Experimental and Molecular Therapeutics<br \/>\n<br \/>Session Title: Antibody Technologies\n<\/p>\n<p><b>Multispecific Antibody Therapeutics<\/b><\/p>\n<p>\nTitle: <i>ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors<br \/>\n<br \/><\/i>Abstract: 2942<br \/>\n<br \/>Session Category: Immunology<br \/>\n<br \/>Session Title: Therapeutic Antibodies 2\n<\/p>\n<p>\nTitle: <i>TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors<br \/>\n<br \/><\/i>Abstract: 5121<br \/>\n<br \/>Session Category: Immunology<br \/>\n<br \/>Session Title: Combination Immunotherapies 2\n<\/p>\n<p>\nTitle: <i>TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors<br \/>\n<br \/><\/i>Abstract: 2982<br \/>\n<br \/>Session Category: Immunology<br \/>\n<br \/>Session Title: Therapeutic Antibodies 3\n<\/p>\n<p>\nTitle: <i>PROTECT\u2122, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action<br \/>\n<br \/><\/i>Abstract: 2926<br \/>\n<br \/>Session Category: Immunology<br \/>\n<br \/>Session Title: Therapeutic Antibodies 2\n<\/p>\n<p>\nTitle: <i>ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity<br \/>\n<br \/><\/i>Abstract: 2935<br \/>\n<br \/>Session Category: Immunology<br \/>\n<br \/>Session Title: Therapeutic Antibodies 2\n<\/p>\n<p><b>Clinical Product Candidates<\/b><\/p>\n<p>\nTitle: <i>ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1, study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers<br \/>\n<br \/><\/i>Abstract: CT278<sup>1<br \/>\n<br \/><\/sup>Session Category: Clinical Trials Posters<br \/>\n<br \/>Session Title: Phase I Clinical Trials 2\n<\/p>\n<p>\nTitle: <i>Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer<br \/>\n<br \/><\/i>Abstract: 2633<br \/>\n<br \/>Session Category: Experimental and Molecular Therapeutics<br \/>\n<br \/>Session Title: Antibody Technologies\n<\/p>\n<p>\nAbstracts can be found on AACR\u2019s website located at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aacr.org&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=www.aacr.org&amp;index=1&amp;md5=6b979a5981d1bcc15dc36612b2c142ce\">www.aacr.org<\/a>. Posters will be available at the time of presentation at the conference on the Company&#8217;s website located at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3742228-1%26h%3D3670077902%26u%3Dhttps%253A%252F%252Fwww.zymeworks.com%252F%26a%3Dwww.zymeworks.com&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=www.zymeworks.com&amp;index=2&amp;md5=debed3ec64f2f1dac8fa801398e6405c\">www.zymeworks.com<\/a>.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i><sup>1<\/sup> Clinical trials abstract texts are embargoed until noon ET on April 14, 2023<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Conference Call and Webcast Information:<\/b><\/p>\n<p>\nZymeworks management will host a conference call and webcast for investors and analysts on April 18, 2023, at 6:30 pm EST. The event will be webcast live with dial-in details and webcast replays available on Zymeworks\u2019 website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations&amp;index=3&amp;md5=4db7bd26d20b11757aecd6aa0d9a4edd\">http:\/\/ir.zymeworks.com\/events-and-presentations<\/a>.\n<\/p>\n<p><b>About Zymeworks Inc.<\/b><\/p>\n<p>\nZymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks&#8217; mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks&#8217; complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks&#8217; proprietary Azymetric\u2122 technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks&#8217; next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks&#8217; proprietary Azymetric\u2122 and ZymeLink\u2122 Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks&#8217; wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3742228-1%26h%3D3670077902%26u%3Dhttps%253A%252F%252Fwww.zymeworks.com%252F%26a%3Dwww.zymeworks.com&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=www.zymeworks.com&amp;index=4&amp;md5=e0acd7fe512afdf358394758fcb223e4\">www.zymeworks.com<\/a> and follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3742228-1%26h%3D2230935422%26u%3Dhttps%253A%252F%252Ftwitter.com%252FZymeworksInc%26a%3D%2540ZymeworksInc&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=%40ZymeworksInc&amp;index=5&amp;md5=122701f71399308e0b4bfe86ca7ed06f\">@ZymeworksInc<\/a> on Twitter.\n<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release includes \u201cforward-looking statements\u201d or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks\u2019 preclinical pipeline; the potential therapeutic effects of zanidatamab and Zymeworks\u2019 other product candidates; Zymeworks\u2019 clinical development of its product candidates and enrollment in its clinical trials; anticipated preclinical and clinical data presentations; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as \u201cplan\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201canticipate\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201ccontinues\u201d, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks\u2019 current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct.\n<\/p>\n<p>\nActual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks\u2019 or its collaborators\u2019 product candidates; clinical trials may not demonstrate safety and efficacy of any of Zymeworks\u2019 or its collaborators\u2019 product candidates; any of Zymeworks\u2019 or its partners\u2019 product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of the COVID-19 pandemic on Zymeworks\u2019 business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks\u2019 behalf, may be more severe and more prolonged than currently anticipated; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under \u201cRisk Factors\u201d in Zymeworks\u2019 quarterly and annual reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for its year ended December 31, 2022 (a copy of which may be obtained at <span class=\"bwuline\"><i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=b5cde00dc48496af3f948e0c65b328c3\">www.sec.gov<\/a><\/i><\/span> and <span class=\"bwuline\"><i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=53361815&amp;newsitemid=20230314005744&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=7&amp;md5=00518f80942b27a7ce83aa4ed8806989\">www.sedar.com<\/a><\/i><\/span>).\n<\/p>\n<p>\nAlthough Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230314005744\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230314005744\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Inquiries:<br \/>\n<br \/>Jack Spinks<br \/>\n<br \/>Director, Investor Relations<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@zymeworks.com\">ir@zymeworks.com<br \/>\n<\/a><\/p>\n<p>Media Inquiries:<br \/>\n<br \/>Diana Papove<br \/>\n<br \/>Director, Corporate Communications<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@zymeworks.com\">media@zymeworks.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Biotechnology Health Pharmaceutical General Health Other Science Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230314005744\/en\/183056\/3\/Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting Eleven abstracts accepted for poster presentation highlight company\u2019s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates Management will host a conference call on April 18th at 6:30 pm Eastern Standard Time (EST) VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 \u2013 19, 2023. \u201cAACR represents an important opportunity for us to share recent progress in developing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740049","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting Eleven abstracts accepted for poster presentation highlight company\u2019s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates Management will host a conference call on April 18th at 6:30 pm Eastern Standard Time (EST) VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 \u2013 19, 2023. \u201cAACR represents an important opportunity for us to share recent progress in developing &hellip; Continue reading &quot;Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T20:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting\",\"datePublished\":\"2023-03-14T20:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"wordCount\":1445,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"name\":\"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-03-14T20:34:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","og_description":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting Eleven abstracts accepted for poster presentation highlight company\u2019s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates Management will host a conference call on April 18th at 6:30 pm Eastern Standard Time (EST) VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 \u2013 19, 2023. \u201cAACR represents an important opportunity for us to share recent progress in developing &hellip; Continue reading \"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T20:34:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting","datePublished":"2023-03-14T20:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/"},"wordCount":1445,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/","name":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-03-14T20:34:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230314005744r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740049"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740049\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}